Cargando…

Axillary lymph node micrometastases decrease triple-negative early breast cancer survival

BACKGROUND: Triple-negative breast cancers (TNBCs) are the most deadly form of breast cancer (BC) subtypes. Axillary lymph node involvement (ALNI) has been described to be prognostic in BC taken as a whole, but its prognostic value in each subtype is unclear. We explored the prognostic impact of ALN...

Descripción completa

Detalles Bibliográficos
Autores principales: Houvenaeghel, G, Sabatier, R, Reyal, F, Classe, J M, Giard, S, Charitansky, H, Rouzier, R, Faure, C, Garbay, J R, Daraï, E, Hudry, D, Gimbergues, P, Villet, R, Lambaudie, E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5117781/
https://www.ncbi.nlm.nih.gov/pubmed/27685443
http://dx.doi.org/10.1038/bjc.2016.283
_version_ 1782468867184918528
author Houvenaeghel, G
Sabatier, R
Reyal, F
Classe, J M
Giard, S
Charitansky, H
Rouzier, R
Faure, C
Garbay, J R
Daraï, E
Hudry, D
Gimbergues, P
Villet, R
Lambaudie, E
author_facet Houvenaeghel, G
Sabatier, R
Reyal, F
Classe, J M
Giard, S
Charitansky, H
Rouzier, R
Faure, C
Garbay, J R
Daraï, E
Hudry, D
Gimbergues, P
Villet, R
Lambaudie, E
author_sort Houvenaeghel, G
collection PubMed
description BACKGROUND: Triple-negative breast cancers (TNBCs) are the most deadly form of breast cancer (BC) subtypes. Axillary lymph node involvement (ALNI) has been described to be prognostic in BC taken as a whole, but its prognostic value in each subtype is unclear. We explored the prognostic impact of ALNI and especially of small size axillary metastases in early TNBCs. METHODS: We analysed in this multicentre study all patients treated for early TNBC in 12 French cancer centres. We explored the correlation between clinicopathological data and ALNI, with a specific focus on the dichotomisation between macrometastases and occult metastases, which is defined as the presence of isolated tumour cells or micrometastases. The prognostic value of ALNI both in terms of disease-free survival (DFS) and overall survival (OS) was also explored. RESULTS: We included 1237 TNBC patients. Five-year DFS and OS were 83.7% and 88.5%, respectively. The identified independent prognostic features for DFS were tumour size >20 mm (hazard ratio (HR)=1.86; 95% CI: 1.11–3.10, P=0.018), lymphovascular invasion (HR=1.69; 95% CI: 1.21–2.34, P=0.002) and ALNI both in case of macrometastases (HR=1.97; 95% CI: 1.38–2.81, P<0.0001) and occult metastases (HR=1.72; 95% CI: 1.1–2.71, P=0.019). DFS and OS were similar between tumours with occult metastases and macrometastases. Tumours presenting at least two pejorative features (out of ALNI, lymphovascular invasion and large tumour size) displayed a significantly poorer DFS in both the training set and validation set, independently of chemotherapy administration. Tumours with no more than one of the above-cited pejorative features had a 5-year OS of ⩾90% vs 70% for other cases (P<0.0001). CONCLUSIONS: Axillary lymph node involvement is a key prognostic feature for early TNBC when isolated tumour cells were identified in lymph nodes. This impact is independent of chemotherapy use.
format Online
Article
Text
id pubmed-5117781
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-51177812017-10-25 Axillary lymph node micrometastases decrease triple-negative early breast cancer survival Houvenaeghel, G Sabatier, R Reyal, F Classe, J M Giard, S Charitansky, H Rouzier, R Faure, C Garbay, J R Daraï, E Hudry, D Gimbergues, P Villet, R Lambaudie, E Br J Cancer Clinical Study BACKGROUND: Triple-negative breast cancers (TNBCs) are the most deadly form of breast cancer (BC) subtypes. Axillary lymph node involvement (ALNI) has been described to be prognostic in BC taken as a whole, but its prognostic value in each subtype is unclear. We explored the prognostic impact of ALNI and especially of small size axillary metastases in early TNBCs. METHODS: We analysed in this multicentre study all patients treated for early TNBC in 12 French cancer centres. We explored the correlation between clinicopathological data and ALNI, with a specific focus on the dichotomisation between macrometastases and occult metastases, which is defined as the presence of isolated tumour cells or micrometastases. The prognostic value of ALNI both in terms of disease-free survival (DFS) and overall survival (OS) was also explored. RESULTS: We included 1237 TNBC patients. Five-year DFS and OS were 83.7% and 88.5%, respectively. The identified independent prognostic features for DFS were tumour size >20 mm (hazard ratio (HR)=1.86; 95% CI: 1.11–3.10, P=0.018), lymphovascular invasion (HR=1.69; 95% CI: 1.21–2.34, P=0.002) and ALNI both in case of macrometastases (HR=1.97; 95% CI: 1.38–2.81, P<0.0001) and occult metastases (HR=1.72; 95% CI: 1.1–2.71, P=0.019). DFS and OS were similar between tumours with occult metastases and macrometastases. Tumours presenting at least two pejorative features (out of ALNI, lymphovascular invasion and large tumour size) displayed a significantly poorer DFS in both the training set and validation set, independently of chemotherapy administration. Tumours with no more than one of the above-cited pejorative features had a 5-year OS of ⩾90% vs 70% for other cases (P<0.0001). CONCLUSIONS: Axillary lymph node involvement is a key prognostic feature for early TNBC when isolated tumour cells were identified in lymph nodes. This impact is independent of chemotherapy use. Nature Publishing Group 2016-10-25 2016-09-29 /pmc/articles/PMC5117781/ /pubmed/27685443 http://dx.doi.org/10.1038/bjc.2016.283 Text en Copyright © 2016 Cancer Research UK http://creativecommons.org/licenses/by-nc-sa/4.0/ From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/
spellingShingle Clinical Study
Houvenaeghel, G
Sabatier, R
Reyal, F
Classe, J M
Giard, S
Charitansky, H
Rouzier, R
Faure, C
Garbay, J R
Daraï, E
Hudry, D
Gimbergues, P
Villet, R
Lambaudie, E
Axillary lymph node micrometastases decrease triple-negative early breast cancer survival
title Axillary lymph node micrometastases decrease triple-negative early breast cancer survival
title_full Axillary lymph node micrometastases decrease triple-negative early breast cancer survival
title_fullStr Axillary lymph node micrometastases decrease triple-negative early breast cancer survival
title_full_unstemmed Axillary lymph node micrometastases decrease triple-negative early breast cancer survival
title_short Axillary lymph node micrometastases decrease triple-negative early breast cancer survival
title_sort axillary lymph node micrometastases decrease triple-negative early breast cancer survival
topic Clinical Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5117781/
https://www.ncbi.nlm.nih.gov/pubmed/27685443
http://dx.doi.org/10.1038/bjc.2016.283
work_keys_str_mv AT houvenaeghelg axillarylymphnodemicrometastasesdecreasetriplenegativeearlybreastcancersurvival
AT sabatierr axillarylymphnodemicrometastasesdecreasetriplenegativeearlybreastcancersurvival
AT reyalf axillarylymphnodemicrometastasesdecreasetriplenegativeearlybreastcancersurvival
AT classejm axillarylymphnodemicrometastasesdecreasetriplenegativeearlybreastcancersurvival
AT giards axillarylymphnodemicrometastasesdecreasetriplenegativeearlybreastcancersurvival
AT charitanskyh axillarylymphnodemicrometastasesdecreasetriplenegativeearlybreastcancersurvival
AT rouzierr axillarylymphnodemicrometastasesdecreasetriplenegativeearlybreastcancersurvival
AT faurec axillarylymphnodemicrometastasesdecreasetriplenegativeearlybreastcancersurvival
AT garbayjr axillarylymphnodemicrometastasesdecreasetriplenegativeearlybreastcancersurvival
AT daraie axillarylymphnodemicrometastasesdecreasetriplenegativeearlybreastcancersurvival
AT hudryd axillarylymphnodemicrometastasesdecreasetriplenegativeearlybreastcancersurvival
AT gimberguesp axillarylymphnodemicrometastasesdecreasetriplenegativeearlybreastcancersurvival
AT villetr axillarylymphnodemicrometastasesdecreasetriplenegativeearlybreastcancersurvival
AT lambaudiee axillarylymphnodemicrometastasesdecreasetriplenegativeearlybreastcancersurvival